Recruiting Alzheimers Disease Studies in Matthews
About Alzheimers Disease Clinical Trials in Matthews
Alzheimer's disease is a progressive brain disorder that destroys memory, thinking skills, and the ability to carry out daily tasks. It is the most common cause of dementia, affecting over 6.7 million Americans age 65 and older. The disease is characterized by amyloid-beta plaques and tau tangles in the brain. Recent FDA approvals of anti-amyloid antibodies like lecanemab (Leqembi) and donanemab have opened a new era of disease-modifying treatments. Clinical trials are now exploring next-generation amyloid-clearing therapies, tau-targeting treatments, anti-inflammatory approaches, and combination strategies. Early-stage patients with mild cognitive impairment or early Alzheimer's are frequently sought for enrollment, and many trials now use blood-based biomarkers for screening.
There are currently 2 alzheimers disease clinical trials recruiting participants in Matthews, NC. These studies are seeking a combined 524 participants. Research is being sponsored by AC Immune SA, GlaxoSmithKline. Clinical trial participation is free and participants receive study-related medical care at no cost.
Alzheimers Disease Clinical Trials in Matthews — FAQ
Are there alzheimers disease clinical trials in Matthews?
Yes, there are 2 alzheimers disease clinical trials currently recruiting in Matthews, NC. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Matthews?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Matthews research site will contact you about next steps.
Are clinical trials in Matthews free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Matthews studies also compensate for your time and travel.
What alzheimers disease treatments are being tested?
The 2 active trials in Matthews are testing new therapies including novel drugs, biologics, and treatment approaches for alzheimers disease.
Data updated July 13, 2026 from ClinicalTrials.gov